ENSIKLOPEDIA Cari Tekan Enter untuk memulai pencarian cepat. Kembali ke Ensiklopedia Arsip Wikipedia Indonesia PL-6983 PL-6983Chemical compound Pharmaceutical compoundPL-6983Clinical dataRoutes ofadministrationSubcutaneous injectionDrug classMelanocortin MC4 receptor agonistIdentifiersCAS Number1966957-74-3PubChem SID472219121 PL-6983 is a synthetic peptide and selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction.[1][2] It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials.[1][2] Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models.[1][2] The drug has reportedly been in pre-clinical development for all medical indications since 2008.[3] Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983."[4] The chemical structure of PL-6983 has yet to be made public. See also List of investigational sexual dysfunction drugs Melanocortin 4 receptor § Agonists References 1 2 3 Simon JA (July 2009). Mitchner N (ed.). "Opportunities for intervention in HSDD" (PDF). The Journal of Family Practice. 58 (7 Suppl Hypoactive): S26–30. PMID 19825316. Archived from the original (PDF) on 2015-05-18. Retrieved 2015-05-14. 1 2 3 Krychman ML, Finestone S (25 October 2010). 100 Questions & Answers About Breast Cancer Sensuality, Sexuality and Intimacy. Jones & Bartlett Publishers. pp. 120–. ISBN 978-1-4496-1936-7. ↑ "Research programme: sexual dysfunction therapy - Palatin Technologies". AdisInsight. Springer Nature Switzerland AG. Retrieved 2019-06-06. ↑ "Palatin Technologies - PL-6983 for Female Sexual Dysfunction". 2015-05-26. Archived from the original on 2015-05-26. External links PL-6983 for Sexual Dysfunction - Palatin Technologies PL-6983 for Female Sexual Dysfunction - Palatin Technologies Palatin Obtains $21.1M to Advance Programs in Female Sexual Dysfunction and Asthma - Genetic Engineering and Biotechnology News Research Programme: Sexual Dysfunction Therapy (PL-6983) - Palatin Technologies - AdisInsight How Sildenax Works? Composition & Benefits of Sildenax - Nutri Medi How Medicines Work To Improve Potency - Vera Farmacia vteSexual dysfunction medicationsDopamine agonists Apomorphine Cabergoline Lisuride Pergolide Piribedil Pramipexole Quinagolide Ropinirole Rotigotine Terguride Melanocortin agonists Bremelanotide Melanotan II PL-6983 PDE5 inhibitors Acetildenafil Aildenafil Avanafil Icariin Lodenafil Mirodenafil Nitrosoprodenafil Sildenafil Sulfoaildenafil Tadalafil Udenafil Vardenafil Sex steroids Androgens (e.g., testosterone, methyltestosterone, other anabolic steroids) Estrogens (e.g., estradiol, ethinylestradiol, conjugated equine estrogens (Premarin)) Progestogens (e.g., progesterone, progestins) Mixed (e.g., tibolone) Others Afrodor (acecarbromal, quebracho, vitamin E) Alkyl nitrites Alprostadil Amantadine Bupropion Buspirone Cyproheptadine Dapoxetine Flibanserin Mirtazapine Moxisylyte Oxytocin Papaverine Phentolamine Psychostimulants (e.g., amphetamines, cocaine, methylphenidate) Rauwolscine (Rauvolfia) Trazodone Yohimbine (Yohimbe) See also: Drugs for erectile dysfunction and premature ejaculation List of investigational sexual dysfunction drugs vteMelanocortin receptor modulatorsMC1Agonists ACTH (corticotropin) Afamelanotide (melanotan I) BMS-470539 Bremelanotide HS-014 HS-024 MSH (α, β, γ) Melanotan II Modimelanotide PL-8177 SHU-8914 SHU-9005 SHU-9119 SNAP-7941 Antagonists ASIP MC2Agonists ACTH (corticotropin) Alsactide Codactide Giractide Norleusactide (pentacosactride) Seractide Tetracosactide (tetracosactrin, cosyntropin) Tosactide (octacosactrin) Tricosactide Tridecactide Antagonists Atumelnant (CRN04894) MC3Agonists ACTH (corticotropin) Afamelanotide (melanotan I) Bremelanotide MSH (α, β, γ) Melanotan II Modimelanotide PG-931 Antagonists AGRP ASIP HS-014 Mifomelatide (TCMCB07) ML-00253764 PG-106 SHU-8914 SHU-9005 SHU-9119 MC4Agonists ACTH (corticotropin) Afamelanotide (melanotan I) AZD2820 BIM-22493 Bivamelagon (LB54640) Bremelanotide LY-2112688 MSH (α, β, γ) Melanotan II MK-0493 Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists LIB-01 (DIC-2024; Libiguin) Antagonists AGRP ASIP HS-014 HS-024 HS-131 JKC-363 MCL-0020 MCL-0042 MCL-0129 ML-00253764 MPB-10 SHU-8914 SHU-9005 SHU-9119 Unknown Semax MC5Agonists ACTH (corticotropin) Afamelanotide (melanotan I) Bremelanotide HS-014 HS-024 MSH (α, β, γ) Melanotan II Modimelanotide SHU-8914 SHU-9005 SHU-9119 Antagonists ASIP ML-00253764 Unknown Semax Unsorted Agonists: Alsactide Codactide Dersimelagon Giractide Norleusactide (pentacosactride) Seractide Tetracosactide (tetracosactrin, cosyntropin) Tosactide (octacosactrin) Tricosactide Tridecactide Others Propeptides: Lipotropin (β, γ) N-POMC (NPP, pro-γ-MSH) Proopiomelanocortin (POMC) This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.vte
